SG11201408330XA - Compositions and methods related to prevention and treatment of rabies infection - Google Patents

Compositions and methods related to prevention and treatment of rabies infection

Info

Publication number
SG11201408330XA
SG11201408330XA SG11201408330XA SG11201408330XA SG11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA
Authority
SG
Singapore
Prior art keywords
international
beijing
prevention
road
treatment
Prior art date
Application number
SG11201408330XA
Inventor
Enyun Shen
Shiqi Ren
Original Assignee
Mountgate Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountgate Group Ltd filed Critical Mountgate Group Ltd
Publication of SG11201408330XA publication Critical patent/SG11201408330XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/174003 A1 (51) International Patent Classification: C07K16/10 (2006.01) A61K39/42 (2006.01) C12N15/13 (2006.01) A61P 31/14 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/CN2012/076012 24 May 2012 (24.05.2012) English (25) Filing Language: (26) Publication Language: English (71) Applicant (for all designated States except US): MOUNT- GATE GROUP LIMITED [GB/GB]; P.O. Box 957 Off­ shore Incorporations Centre Road Town, Tortola (VG). (72) Inventors; and (75) Inventors/Applicants (for US only): SHEN, Enyun [CN/CN]; Tower 15, No. 26 Xihuan South Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). REN, Shiqi [CN/CN]; Tower 15, No. 26 Xihuan South Road, Beijing Economic-Technological De­ velopment Area, Beijing 100176 (CN). (74) Agent: TDIP & PARTNERS; Room 2002 A-Building, North Ring Center, No. 18 Yumin Road, Xicheng District, Beijing 100029 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS AND METHODS RELATED TO PREVENTION AND TREATMENT OF RABIES INFECTION FIG. 1 30000-1 20000- 3 —I 0£ 10000- m o o •t i> 3D11E3 3H10D3 5A1C10 6F11C1 -O- 7G11A3 0.64 3.2 16 80 400 200010000 Concentration of RVNA (ng/mL) i-H (57) Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind and neutralize rabies virus. Antibod to - ® ies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of ra - CJ o & bies infection.
SG11201408330XA 2012-05-24 2012-05-24 Compositions and methods related to prevention and treatment of rabies infection SG11201408330XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/076012 WO2013174003A1 (en) 2012-05-24 2012-05-24 Compositions and methods related to prevention and treatment of rabies infection

Publications (1)

Publication Number Publication Date
SG11201408330XA true SG11201408330XA (en) 2015-01-29

Family

ID=49623026

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408330XA SG11201408330XA (en) 2012-05-24 2012-05-24 Compositions and methods related to prevention and treatment of rabies infection

Country Status (12)

Country Link
US (1) US9290564B2 (en)
EP (2) EP3508497A1 (en)
JP (1) JP5868549B2 (en)
KR (1) KR101937733B1 (en)
CN (1) CN104603149B (en)
BR (1) BR112014029274B1 (en)
HK (1) HK1210187A1 (en)
IN (1) IN2014KN02831A (en)
MX (1) MX369626B (en)
PH (1) PH12014502628B1 (en)
SG (1) SG11201408330XA (en)
WO (1) WO2013174003A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603149B (en) * 2012-05-24 2017-06-30 万机集团有限公司 The composition related to prevention and treatment rabies infection and method
CN104193823B (en) * 2014-08-22 2019-06-11 兰州生物制品研究所有限责任公司 A kind of anti-rabies virus specificity human antibody and application
US10988531B2 (en) * 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3831404A1 (en) * 2014-11-18 2021-06-09 Humabs Biomed S.A. Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
CA2995109A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof
AR108516A1 (en) 2016-05-18 2018-08-29 Boehringer Ingelheim Int ANTI-PD1 AND ANTI-LAG3 ANTIBODY MOLECULES FOR CANCER TREATMENT
KR101990795B1 (en) * 2017-12-07 2019-06-19 대한민국 Rabies virus-specific antibody and detecting method of rabies virus using thereof
CN109970852B (en) * 2019-04-01 2020-10-13 浙江大学 Hybridoma cell strain secreting anti-rabies virus M protein monoclonal antibody and application
CN111171145B (en) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 Anti-rabies virus monoclonal antibody, preparation method and application
CN111888470A (en) * 2020-08-12 2020-11-06 赵静 Flushing fluid with rabies virus neutralizing effect and activity detection method thereof
WO2023215746A2 (en) * 2022-05-02 2023-11-09 Javelin Oncology, Inc. Anti-alppl2 antibodies and chimeric antigen receptors, and compositions and methods of use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5028530A (en) 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
EP0229046B1 (en) 1985-03-30 1994-05-04 BALLIVET, Marc Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (en) 1986-04-09 2007-05-16 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
ATE309376T1 (en) 1990-06-28 2005-11-15 Hoechst Ag FUSION PROTEINS WITH IMMUNGLOBULIN COMPONENTS, THEIR PRODUCTION AND USE
US5304389A (en) 1991-06-18 1994-04-19 Mitsubishi Kasei Corporation Non-hygroscopic icing composition
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
ES2129029T5 (en) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. DIRECT IMMUNOSTIMULATION WITH BISPECIFIC REAGENTS.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
US6106835A (en) 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
DE69214709T2 (en) 1991-04-26 1997-02-20 Surface Active Ltd New antibodies and methods of using them
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BINDING PAIRS
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DK0605522T3 (en) 1991-09-23 2000-01-17 Medical Res Council Process for producing humanized antibodies
DE69233408T2 (en) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Production of Antibodies on Phage Surfaces Starting from Antibody Segment Libraries.
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
US7094571B2 (en) 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7083945B1 (en) 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
CN103596975A (en) * 2010-01-04 2014-02-19 印度免疫有限公司 Recombinant human bivalent diabody against rabies virus and uses thereof
CN101812132B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab3) against rabies virus glycoprotein
CN101812130B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab5) against rabies virus glycoprotein
CN101812131B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab8) against rabies virus glycoprotein
CN104603149B (en) * 2012-05-24 2017-06-30 万机集团有限公司 The composition related to prevention and treatment rabies infection and method

Also Published As

Publication number Publication date
EP2855521A1 (en) 2015-04-08
JP2015525206A (en) 2015-09-03
CN104603149B (en) 2017-06-30
US20150110781A1 (en) 2015-04-23
EP3508497A1 (en) 2019-07-10
BR112014029274B1 (en) 2022-02-15
KR20150016590A (en) 2015-02-12
MX369626B (en) 2019-11-13
WO2013174003A1 (en) 2013-11-28
IN2014KN02831A (en) 2015-05-08
JP5868549B2 (en) 2016-02-24
HK1210187A1 (en) 2016-04-15
PH12014502628A1 (en) 2015-01-26
CN104603149A (en) 2015-05-06
PH12014502628B1 (en) 2015-01-26
US9290564B2 (en) 2016-03-22
EP2855521A4 (en) 2016-03-02
BR112014029274A2 (en) 2018-04-24
KR101937733B1 (en) 2019-01-11
MX2014014412A (en) 2015-07-21

Similar Documents

Publication Publication Date Title
SG11201408330XA (en) Compositions and methods related to prevention and treatment of rabies infection
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201407233RA (en) Ethylene oligomerization process
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201406977TA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201407774XA (en) Conversion of biomass
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201407265RA (en) Novel ha binding agents
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof